Influence of CYP3A5 Polymorphism on Liver Function Abnormality and the Trough Level Change After Conversion

NCT02882113 · clinicaltrials.gov ↗

PHASE4

Phase

UNKNOWN

Status

60

Enrollment

OTHER

Sponsor class

Conditions

Liver Dysfunction

Interventions

DRUG: Advagraf

Sponsor

Seoul National University Hospital